209 related articles for article (PubMed ID: 8674964)
41. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
43. Paucibacillary treatment for large tuberculoid lesions of leprosy?
Santos MN; de Ferreira LC; Talhari S
Int J Lepr Other Mycobact Dis; 2005 Sep; 73(3):225-7; author reply 227-8. PubMed ID: 16830649
[No Abstract] [Full Text] [Related]
44. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
Chandorkar AG; Burte NP; Gade RK; Bulakh PM
Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
[TBL] [Abstract][Full Text] [Related]
45. An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of fixed duration therapy.
Mathew D; Kishore BN; Shwethadri GK; Sukumar ; Shetty NJ
Indian J Lepr; 2004; 76(1):11-8. PubMed ID: 15527055
[TBL] [Abstract][Full Text] [Related]
46. Half a Century in Hiding: A Unique Case of Tuberculoid Leprosy with an Unprecedented Incubation Period.
Rajani AJ; Raval DM; Chitale RA; Kempaiah P; Elwasila SM; Durvasula R; Oring J
Am J Case Rep; 2024 Feb; 25():e942048. PubMed ID: 38351602
[TBL] [Abstract][Full Text] [Related]
47. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions.
Silva EA; Iyer A; Ura S; Lauris JR; Naafs B; Das PK; Vilani-Moreno F
Trop Med Int Health; 2007 Dec; 12(12):1450-8. PubMed ID: 18076551
[TBL] [Abstract][Full Text] [Related]
48. A case of relapse with drug-susceptible M. leprae after multidrug therapy.
Constant-Desportes M; Guelpa-Lauras CC; Carolina JC; Léoture A; Grosset JH; Sansarricq H
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):242-7. PubMed ID: 2071981
[TBL] [Abstract][Full Text] [Related]
49. Relapse of paucibacillary leprosy after short course multidrug therapy.
Pavithran K
Indian J Lepr; 1988 Apr; 60(2):225-9. PubMed ID: 3192971
[TBL] [Abstract][Full Text] [Related]
50. Lepromatous leprosy.
Booth AV; Kovich OI
Dermatol Online J; 2007 Jan; 13(1):9. PubMed ID: 17511942
[TBL] [Abstract][Full Text] [Related]
51. Coexistence of borderline tuberculoid Hansen's disease with tuberculosis verrucosa cutis in a child--a rare case.
Ravindra K; Sugareddy ; Ramachander T
Indian J Lepr; 2010; 82(2):91-3. PubMed ID: 21434512
[TBL] [Abstract][Full Text] [Related]
52. A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.
Kar PK; Arora PN; Ramasastry CV; Dhaka RS
J Indian Med Assoc; 1994 Oct; 92(10):336-7. PubMed ID: 7822849
[TBL] [Abstract][Full Text] [Related]
53. Lichen scrofulosorum caused by Mycobacterium leprae: first report.
Fiallo P; Cabiddu F; Clapasson A; Parodi A
Int J Dermatol; 2014 Oct; 53(10):1244-8. PubMed ID: 25041689
[TBL] [Abstract][Full Text] [Related]
54. Sparing of tuberculoid leprosy patch in a patient with dapsone hypersensitivity syndrome.
Ng PP; Goh CL
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):646-8. PubMed ID: 9777777
[No Abstract] [Full Text] [Related]
55. Histopathological study of apparently normal skin of patients with leprosy.
El-Darouti MA; Hussein S; Marzouk SA; Nabil N; Hunter NS; Mahgoub D; El-Eishi NH; Abdel-Halim MR
Int J Dermatol; 2006 Mar; 45(3):292-6. PubMed ID: 16533232
[TBL] [Abstract][Full Text] [Related]
56. Reactional tattoo inoculation borderline tuberculoid leprosy with oedematous tattoos.
Ghorpade A
Lepr Rev; 2004 Mar; 75(1):91-4. PubMed ID: 15072131
[TBL] [Abstract][Full Text] [Related]
57. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
[TBL] [Abstract][Full Text] [Related]
58. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction.
Moura DF; Teles RM; Ribeiro-Carvalho MM; Teles RB; Santos IM; Ferreira H; Fulco TO; Nery JA; Sampaio EP; Sarno EN
Br J Dermatol; 2007 Aug; 157(2):273-83. PubMed ID: 17553031
[TBL] [Abstract][Full Text] [Related]
59. Total agranulocytosis caused by dapsone therapy for tuberculoid leprosy--an unappreciated serious side effect of anti-leprosy treatment with clinical implications.
Satarasinghe RL; Jayawardana MA; De Silva GV; Murugathas S; Riyaaz AA; Wickrmasingha UD; Wijesinghe R
Drug Metabol Drug Interact; 2009; 24(2-4):325-9. PubMed ID: 20408505
[TBL] [Abstract][Full Text] [Related]
60. Role of S-100 staining in differentiating leprosy from other granulomatous diseases of the skin.
Thomas MM; Jacob M; Chandi SM; George S; Pulimood S; Jeyaseelan L; Job CK
Int J Lepr Other Mycobact Dis; 1999 Mar; 67(1):1-5. PubMed ID: 10407622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
